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Abstract
Background: Artemisinin-based combination therapy (ACT) is currently recommended as first-line treatment for
uncomplicated malaria, but of concern, it has been observed that the effectiveness of the main artemisinin
derivative, artesunate, has been diminished due to parasite resistance. This reduction in effect highlights the
importance of the partner drugs in ACT and provides motivation to gain more knowledge of their pharmacokinetic
(PK) properties via population PK studies. Optimal design methodology has been developed for population PK
studies, which analytically determines a sampling schedule that is clinically feasible and yields precise estimation of
model parameters. In this work, optimal design methodology was used to determine sampling designs for typical
future population PK studies of the partner drugs (mefloquine, lumefantrine, piperaquine and amodiaquine)
co-administered with artemisinin derivatives.
Methods: The optimal designs were determined using freely available software and were based on structural PK models
from the literature and the key specifications of 100 patients with five samples per patient, with one sample taken on the
seventh day of treatment. The derived optimal designs were then evaluated via a simulation-estimation procedure.
Results: For all partner drugs, designs consisting of two sampling schedules (50 patients per schedule) with five samples
per patient resulted in acceptable precision of the model parameter estimates.
Conclusions: The sampling schedules proposed in this paper should be considered in future population
pharmacokinetic studies where intensive sampling over many days or weeks of follow-up is not possible due to either
ethical, logistic or economical reasons.
Keywords: Artemisinin-based combination therapy, Partner drugs, Optimal design
Background
Despite substantial progress in the last decade, malaria
remains a major global health problem [1]. In 2009 there
were an estimated 225 million cases and 781,000 malaria-
related deaths [2]. Artemisinin-based combination therapy
(ACT) is recommended as first-line treatment for uncom-
plicated falciparum malaria [3]. The primary antiparasitic
agent in ACT is the artemisinin derivative, which is quickly
absorbed by and eliminated from the body, and destroys
the majority of detectable parasites within the first 3 days
of treatment. The partner drug(s) co-administered with the
artemisinin derivative is less effective but slowly eliminated,
and thus provides residual antiparasitic activity in the
patient. Additionally, the partner drug offers protection to
the artemsinin derivative from rare mutant parasites that
have developed resistance [3].
Though the artemisinin derivitives are generally effect-
ive, it has been observed in Cambodia that the effective-
ness of the main artemisinin derivative, artesunate, has
been diminished due to parasite resistance [4]. These
findings highlight the necessity and importance of the
partner drugs in ACT, and provide impetus for gaining
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more knowledge of their pharmacokinetic (PK) properties.
This knowledge can ultimately be used to optimize dosing
regimens, particuarly for high risk groups such as pregnant
women and children.
The PK properties of a drug can be characterized for
intended target populations via population PK studies. For
anti-malarial drugs, these studies need to be large enough
and designed in order to be representative for the target
population(s) so that the expected concentration-time
profile and between-subject variability parameters can be
characterized adequately [5]. From a modelling perspective,
it would be ideal to propose study designs with intensive
blood sampling, but often this is not realistic for patients
presenting with falciparum malaria. Intensive sampling
over the entire follow-up period is logistically difficult,
especially in rural settings where outpatients attend few
follow-up visits [5]. However, population PK modelling
allows information to be “borrowed” across individuals to
obtain parameter estimates [6,7]; therefore it is reasonable to
propose study designs with fewer samples per patient but a
sufficiently large number of patients. The key aspect of such
a design lies with the timing of blood samples, since the
times at which the samples are taken must provide sufficient
information for precise estimation of model parameters.
Optimal design methodology has been developed for
designing population PK studies [8]; the method analytic-
ally determines a blood sampling schedule that provides
precise estimates of the model parameters. Importantly,
the methodology allows economical use of resources [6],
for which in the case of the partner drugs is fewer samples
per patient but with more patients enrolled. The overall
aim of this work was to determine optimal blood sampling
schedules that can be used to study the partner drugs of
the most widely used ACT that are economical, efficient,
and appropriate for all target populations.
Methods
Determination of the optimal designs
For each partner drug (mefloquine, lumefantrine, pipera-
quine and amodiaquine), an optimal design for a com-
bined study population of non-pregnant adults, pregnant
women and children was determined using D-optimal
design theory. In brief, a D-optimal design is the design
that maximizes the determinant of the population Fisher
Information matrix, yielding the smallest possible standard
errors. For full details, see [8].
The designs were determined using POPT [9], which
implements D-optimal design methodology. Thus for
each partner drug:
1. population PK models (and the associated parameter
values) for non-pregnant adults, pregnant women
and children were identified from the literature and
entered into POPT,
2. the key constraints of 100 patients, five plasma
samples per patient (including one sample on the
seventh day of treatment) and two sampling designs
(groups) were specified,
3. optimal sampling times for the combined population
of pregnant women, non-pregnant adults and
children were determined, and
4. sampling windows (time intervals containing the
optimal sampling times) were derived.
The key specifications of 100 patients and five blood
samples per patient were consistent with the sampling
constraints reported in a survey administered to 22
malaria researchers with extensive experience in conduct-
ing PK studies in Asia and Africa [10] and World Health
Organization guidelines for sampling schemes for pharma-
cokinetic studies of anti-malarial drugs [5]. A fixed sample
on the seventh day of treatment was chosen since it has
been recommended that a day 7 plasma drug concentra-
tion should be collected as a routine part of anti-malarial
drug trials, particularly for the partner drugs given with
artemisinin derivatives [5,11]. The day 7 concentration is
generally within the assay limits of quantification and has
been shown to be predictive of treatment failure [5,11].
Two sampling designs (i.e. two groups with different
sampling schedules; n = 50 for each group) were specified
to provide (i) adequate coverage of the PK profiles, since
each patient contributes only five samples and the drugs
are eliminated over several weeks, and (ii) flexibility with
sampling, since one sampling schedule may be too restrict-
ive for an outpatient cohort. The dosing regimens for all
drugs were in concordance with the World Health
Organization guidelines for the treatment of malaria [3].
The structural PK models that were considered for each
design are displayed in Figures 1 and 2 (in the figures, the
PK parameters were set to the reported population values).
The mefloquine design was based on one-compartment
population PK models reported for Thai children [12] and
pregnant women [13], as well as two-compartment models
reported for African adults [14]. Two optimal designs were
determined for mefloquine: one for the dosing regimen of
8.3 mg/kg at 0, 24 and 48 h and another for 15 mg/kg
at 24 h and 10 mg/kg at 48 h. The optimal design for
lumefantrine was based on two-compartment models
reported for Thai adults [15] and pregnant women [16],
and a one-compartment model reported for Tanzanian
children [17]. The design for piperaquine was based on
two-compartment models reported for adults and children
in Cambodia [18] and Thailand [19]. At the time the
designs were determined there were no published popula-
tion PK models for piperaquine in pregnant women, so PK
profiles for this group were derived from results reported
in [19] and a pseudo-pregnant state was simulated by
increasing the clearance and volume parameters by 40
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and 30%, respectively. For amodiaquine, the design was
determined for the active metabolite, desethylamodiaquine.
The design was based on two-compartment models
reported in African children [20,21] and adults [22], as well
as an unpublished two-compartment model for Thai
pregnant and post-partum women (listed in Additional file
1 with a full description of how this model was entered into
POPT). The model reported in [22] was approximated by a
two-compartment model based on an analysis of simulated
desethylamodiaquine concentrations from the reported
parent-metabolite model. For full details of each model see
[12-23].
For each structural model entered into POPT, the PK
parameter values were set to the population mean esti-
mates (displayed graphically in Figures 1 and 2) and the
lower and upper bounds of their respective 95% confi-
dence intervals. A weighting of 95% was allocated to the
models where the PK parameters were set to the popula-
tion estimates and likely ranges of age and/or body weight
were considered for each model. The between-subject
variability (BSV) parameters were set to the reported
population mean estimates, and if not reported the BSV of
the absorption rate constant (ka) was set to 50% and the
BSVs for other parameters were set to 30%. These values
were based on a summary of the literature of PK studies for
anti-malarial drugs [5] and the authors’ previous experience
with other drugs. The proportional and additive residual
variability parameters were also set to their reported popu-
lation estimates. If the additive component was not reported
it was set to a plausible value from another study of the
same drug, and if the proportional component was not
reported it was set to 10% (again based on [5] and previous
experience with other drugs).
To ensure the designs were clinically feasible, sampling
windows were derived in POPT. A sampling window is a
time interval of acceptable sub-optimality such that
any set of samples taken within the windows ensures
minimal impact on the standard errors of the estimated
parameters. For all designs, the windows were con-
structed such that there would be at worst a 20% relative
increase in the standard errors compared to the optimal
sampling times.














































8.3 mg/kg at 0, 24, 48 h
(entire follow−up)
Non−pregnant adults, Ashley et al.
Non−pregnant adults (SR), Svensson et al.
Non−pregnant adults (RS), Svensson et al.
Pregnant women, Nabangchang et al.
Children (split dose), Simpson et al.
Children (single dose), Simpson et al.














































15 mg/kg at 24 h, 10 mg/kg at 48 h
(entire follow−up)
Non−pregnant adults, Ashley et al.
Non−pregnant adults (SR), Svensson et al.
Non−pregnant adults (RS), Svensson et al.
Pregnant women, Nabangchang et al.
Children (split dose), Simpson et al.
Children (single dose), Simpson et al.
Figure 1 Structural pharmacokinetic models considered for the mefloquine optimal designs, with parameter values set to the reported
population estimates. The optimal sampling windows are displayed on the time axes.
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Non−pregnant adults, Ezzet et al.
Pregnant women, Tarning et al.
Children, Hietala et al.


















































Non−pregnant adults, Tarning et al.
Non−pregnant adults, Hung et al.
Pregnant women, based on Tarning et al.
Children, Hung et al.














































Children, Stepniewska et al.
Children, Hietala et al.
Non−pregnant adults, based on Jullien et al.
Pregnant and post−partum women, Tarning et al. (unpublished)
Pregnant and post−partum women, Tarning et al. (unpublished)
Figure 2 Structural pharmacokinetic models considered for the lumefantrine, piperaquine and desethylamodiaquine optimal designs,
with parameter values set to the reported population estimates. The optimal sampling windows are displayed on the time axes.
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Evaluation of the optimal designs
The robustness of the optimal designs was evaluated by
a simulation-estimation procedure that was automated
in NONMEM 7.1 [24]. So for each optimal design:
1. 100 datasets were simulated, where each dataset
consisted of 100 virtual patients: 33 non-pregnant
adults, 33 pregnant women and 34 children. This
was done to mimic the clinically realistic scenario of
adults and children being enrolled in the same study.
Body weights for each of these groups were
simulated from distributions that were consistent
with those reported in the literature.
2. Individual drug concentrations were simulated at the
optimal sampling times from a respective population
PK model.
3. Each simulated dataset was analysed with NONMEM
using the FOCE with INTERACTION method. The
M3 method was used when 10% or more of the
simulated concentrations fell below the lower limit
of quantification [24,25]. For each dataset, the non-
pregnant adults, pregnant women and children were
analysed separately. This was done to mimic a “worst
case” scenario where the patient groups could not be
modelled together (e.g. with indicator variables on the
PK parameters). An estimation run was considered
successful if NONMEM declared successful
minimization of the objective function or reported a
termination due to rounding errors (error code 134).
The latter condition was considered a “successful” run
since it can usually be remedied by altering the
starting values.
4. For each estimated parameter, empirical percent
relative standard errors (%RSEs) were computed.
This was done by dividing the standard deviation of
the estimates from the analyses by the median and
multiplying by 100. The empirical %RSEs were
compared with the expected %RSEs from POPT.
For the mefloquine design, data were simulated from and
analysed with one-compartment models reported in
[12,13,23] (children, non-pregnant adults and pregnant
women). Additionally, non-pregnant adult data were simu-
lated from and analysed with a two-compartment model
reported in [14] (SR enantiomer). For the lumefantrine
design PK data for non-pregnant adults and pregnant
women were simulated from and analysed with two-
compartment models reported in [15] and [16], respectively.
Lumefantrine profiles for children were simulated from and
analysed with the one-compartment model reported in [17].
For the piperaquine design, non-pregnant adult and paedi-
atric data were simulated from and analysed with two-com-
parment models reported in [19] and [18] (respectively). In
addition, piperaquine profiles for children, pregnant and
non-pregnant women were simulated from very recent
models reported in [26] and [27] (three-compartment mod-
els with n-transit absorption) and analysed with two-com-
partment models. For the desethylamodiaquine design, data
for children were simulated from and analysed with the
two-compartment model reported in [21]. For the adults,
desethylamodiaquine concentrations were simulated from
and analysed with the unpublished two-compartment
model provided by JT. This model assumed that pregnancy
did not affect the PK of desethylamodiaquine, therefore
only a single adult simulation-estimation procedure was
performed (n=66, with allometric scaling on clearance and
volume parameters). See Additional file 1 for more details
on how this model was employed for the evaluation of this
design. The simulation-estimation procedure was not per-
formed for the model approximated from [22] since this
model was based on simulated concentrations.
Results
Optimal designs
Table 1 shows the optimal sampling times and sampling
windows for each partner drug design and Figures 1 and
2 display the sampling windows graphically. For the
mefloquine, piperaquine and desethylamodiaquine designs,
it was specified in POPT for all patients to have one sample
taken on the first and second days of treatment and three
samples taken over the remainder of the follow-up period.
For the lumefantrine design, patients in the first sampling
schedule (Group 1 in Table 1) were assigned to have one
sample taken on the first and second days of treatment and
three samples taken over the rest of the follow-up, and
patients in the second sampling schedule (Group 2 in
Table 1) were specified to have one sample taken on the
first, second and third days with an additional two samples
taken over the follow-up.
Evaluation of the optimal designs
Additional file 1: Table S2 reports the expected and empir-
ical %RSEs for the mefloquine optimal design employing a
dosing regimen of 8.3 mg/kg daily for 3 days and Additional
file 1: Table S3 displays the same information using a dosing
regimen of 15 mg/kg on the second day of artesunate/mef-
loquine combination therapy and 10 mg/kg on the third
day. For all study populations, the one-compartment mod-
els exhibited acceptable empirical %RSEs for the PK, BSV
and residual variance parameters (≲ 25%, ≲ 60%, ≲z 50%,
respectively). The only exception was the BSV of CL/F for
children in Additional file 1: Table S3, which was slightly
high. When attempting to estimate all parameters of the
two-compartment model reported for non-pregnant adults,
the empirical %RSEs for the PK parameters were satisfac-
tory but unacceptably high (≥ 100%) for the BSVs of inter-
compartmental clearance (Q/F) and Vp/F. Therefore the
BSV of Q/F was fixed to the value it was simulated at. This
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resulted in acceptable empirical %RSEs in Additional file 1:
Table S3 (though slightly high for Q/F), and for Additional
file 1: Table S2 resulted in a high but reduced empirical %
RSE for the BSV of Vp/F and slightly high %RSEs for Q/F
and Vp/F. All other empirical %RSEs in Additional file 1:
Table S2 were acceptable.
Additional file 1: Table S4 reports the expected and
empirical %RSEs for the lumefantrine optimal designs.
The design yielded sufficient information for the esti-
mation of two-compartment model parameters
reported for pregnant women. The empirical %RSEs
for the one-compartment model reported in children
were acceptable with the exception of ka, which was
nearly twice as high as the nominal 25%. Due to a struc-
tural identifiability problem with the model reported for
non-pregnant adults, the absorption rate constant (ka) was
declared as fixed in POPT for the non-pregnant adults, as
well as the BSVs of ka and Vp/F . Consequently, ka and its
BSV were fixed in the estimation step of the evaluation pro-
cedure and the BSVs of Q/F and Vp/F were omitted. After
these adjustments, the empirical %RSEs for the estimated
parameters were satisfactory.
Additional file 1: Table S5 displays the results from the
evaluation of the piperaquine design. For the non-preg-
nant adult model reported in [19], the design yielded
acceptable precision for all of the PK parameters with the
exception of ka, which displayed an empirical %RSE that
was high but less than 50%. The empirical precision for
the BSVs of CL/F, Q/F and Vp/F was marginally higher
than the nominal 60% and for the BSVs of ka and Vc/F
was acceptable. All parameters of the two-compartment
model fitted to the simulated data for non-pregnant
women displayed acceptable empirical precision. For the
paediatric model reported in [18], the BSVs of Vc/F, Q/F
and Vp/F were declared as fixed in POPT due to unac-
ceptably high expected %RSEs (>100%). These parameters
were reported to have additive between-subject variability,
which was specified in POPT. However, in the simulation-
estimation procedure it was assumed that all PK para-
meters were lognormally distributed, which resulted in
satisfactory empirical precision for all parameters except
the BSV of Vc/F (see Discussion for a full description of
the rationale). The two-compartment model fitted to
paediatric data simulated from the model reported in [26]
displayed acceptable empirical %RSEs for all parameters.
Additional file 1: Table S6 shows the expected and
empirical %RSEs for the desethylamodiaquine optimal
design. For the children the empirical %RSEs for all
reported parameters were acceptable. For the adults,
acceptable empirical precision was observed for all
Table 1 Optimal sampling times (h) and sampling windows for each drug
Drug Optimal times
(sampling windows)
Mefloquine (8.3 mg/kg at 0, 24 and 48 h) Group 1: 3.22 43.0 147* 496 1035
(n = 50) (2.35, 4.11) (39.4, 47.6) (139, 158) (457, 546) (988, 1058)
Group 2: 2.02 28.0 67.8 147* 538
(n = 50) (1.49, 2.81) (26.7, 29.6) (62.7, 75.8) (139, 158) (456, 593)
Mefloquine (15 mg/kg at 24 h, 10 mg/kg at 48 h) Group 1: 26.5 66.9 147* 544 1011
(n = 50) (25.8, 27.8) (60.8, 71.7) (134, 158) (501, 593) (971, 1058)
Group 2: 26.5 66.3 66.5 147* 694
(n = 50) (25.8, 27.5) (60.5, 71.6) (60.5, 71.7) (141, 158) (650, 776)
Lumefantrine (12 mg/kg at 0, 8, 24, 36, 48 and 60 h) Group 1: 2.28 30.3 100 147* 267
(n = 50) (1.78, 2.78) (28.1, 31.7) (86.9, 110) (132, 159) (231, 310)
Group 2: 11.6 37.7 53.7 147* 218
(n = 50) (10.1, 13.4) (37.7, 41.6) (52.3, 56.6) (130, 149) (203, 261)
Piperaquine (18 mg/kg at 0, 24 and 48 h) Group 1: 0.18 30.0 77.3 147* 705
(n = 50) (0.10, 0.61) (29.1, 31.9) (72.3, 84.9) (138, 156) (652, 747)
Group 2: 2.54 24.0 147* 358 1291
(n = 50) (2.15, 3.95) (24.0, 24.6) (138, 155) (259, 382) (1204, 1322)
Desethylamodiaquine (10 mg/kg of amodiaquine at 0, 24 and 48 h) Group 1: 9.67 24.0 147* 348 651
(n = 50) (7.03, 10.1) (24.0, 24.1) (129, 157) (339, 398) (599, 651)
Group 2: 0.71 24.0 98.0 147* 348
(n = 50) (0.38, 1.36) (24.0, 24.1) (88.4, 106) (129, 157) (316, 397)
*3rd hour of the seventh day of treatment.
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parameters of the unpublished two-compartment model
(see Additional file 1 for model details).
Discussion
This study proposes optimal designs that can be used
prospectively to study the population pharmacokinetics of
the partner drugs used with the most widely used ACT.
The designs were based on models from the literature and
the key specifications of 100 patients with five samples
per person. The sampling schedules for each drug are
applicable to the target populations of non-pregnant
adults, pregnant women and children. Sampling windows
were derived for each optimal sampling time, which pro-
vide flexibility for taking samples in the field and capture
standard days of follow-up for clinical studies (days 1, 2, 3,
7, 14, 21, 28, 35, 42, 49, 56 and 63).
The design for mefloquine was based primarily on
one-compartment models, which in general displayed
acceptable expected and empirical precision for all target
populations. The only exception was the BSV of CL/F for
children in Additional file 1: Table S3, but this result was
due to the conservative approach to evaluating the designs.
The designs were derived in POPT assuming 100 patients,
which means that the expected %RSEs were calculated
assuming 100 patients for any given competing model.
However, the simulation-estimation procedure was per-
formed on only 33 or 34 patients. To ensure the design
provided adequate information for children receiving two
doses of mefloquine, the simulation-estimation procedure
was performed again with 50 simulated children and
resulted in acceptable empirical %RSEs for all parameters.
Empirical precision was not ideal for all parameters of
the two-compartment model for non-pregnant adults, but
again, this was due to the conservative evaluation pro-
cedure. The simulation-estimation procedure was per-
formed again with 65 simulated adult patients and resulted
in acceptable empirical %RSEs for all parameters. Therefore
the proposed design should be sufficient for estimating a
two-compartment model for non-pregnant adults, and as
more studies are conducted the designs can be updated to
provide more information for estimating two-compartment
models in all populations.
The lumefantine design resulted in precise estimation of
the two-compartment model parameters for pregnant
women. The design yielded acceptable precision for the
estimable parameters for the non-pregnant adults, but was
not optimized for ka or the BSVs of ka or Vp/F for this
group due to a structural identifiability problem with the
model reported in [15]. This issue was explored in POPT
by increasing the number of samples to eight per patient,
but still resulted in unacceptably high expected %RSEs for
these parameters. This model was entered into POPT
since it was the only published model for non-pregnant
adults, however it is likely that other two-compartment
profiles exist for this group. Therefore, it is recommended
to vary sampling within the windows for non-pregnant
adults to investigate other plausible parameter values. For
the children, the design provided adequate information for
most of the one-compartment model parameters reported
in [17], however, the reported model was estimated
from concentrations that were taken only up to 72 h,
which is well before the distribution phase is complete
(approximately 14 days). Thus there may be other plausible
structural PK models for children (e.g. a two-compartment
model, which is quite likely given the adult profiles), and it
is, therefore, recommended to vary sampling within the
windows to provide means for exploring alternative
structural models for this group. As more population PK
studies of lumefantrine are performed, this design will
be updated to account for other reported models in all
study populations, particularly those in children and
non-pregnant adults.
The piperaquine design was based on two-compartment
models and exhibited acceptable expected precision of all
estimable parameters for all study populations. For the
non-pregnant adults, the empirical %RSEs for ka and the
BSVs of CL/F, Q/F and Vp/F were slightly greater than
the target values, but as with the mefloquine design this
was due to the conservative approach to evaluation. The
simulation-estimation procedure was repeated for this
group with 50 patients per simulated dataset and
resulted in acceptable %RSEs for all parameters. The
two-compartment models fitted to data simulated from
models reported in [27] for pregnant and non-pregnant
women yielded acceptable empirical precision for all
parameters. The simulation models used for these
evaluations provided a detailed description of the PK for
these groups (three compartment models with n-transit
absorption), and under the proposed design allowed the
two-compartment models to be fitted with a lag-time
(fixed) as well as covariances on the BSVs (CL/F,Vc/F, Q/
F and Vp/F). This empirical result provides evidence that
the proposed sampling schedules should be sufficient
for estimating two-compartment models in these patient
groups. The design was not optimized for the BSVs of
Vc/F, Q/F and Vp/F reported in [18] for children since
POPT gave unacceptably high expected %RSEs. However,
these parameters were reported to have additive between-
subject variability, thus these BSVs were declared as
additive in POPT. Though it is possible that the
between-subject variability for these parameters is truly
additive, it is biologically plausible and thus common
practice to assume exponential between-subject vari-
ability for all PK parameters. Consequently, the simula-
tion-estimation procedure for children was performed
assuming exponential between-subject variability, and
resulted in acceptable empirical precision for all para-
meters except the BSV of Vc/F. Again, this result was
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due to the conservative approach to evaluating the
designs, and when repeated with 50 patients per simu-
lated dataset all parameters displayed acceptable %RSEs.
The two-compartment model fitted to the simulated
paediatric data from [26] yielded acceptable empirical
precision for all parameters. As with the adults, the
simulation model used for this evaluation provided a
detailed description of the PK for this group, and under
the proposed design allowed estimation of covariances
between the BSV parameters. Therefore the proposed
optimal design should provide reasonable means for
estimating two-compartment models in all patient
populations, and it is recommended to vary sampling
within the windows to gain more knowledge of their PK
profiles.
The design for desethylamodiaquine resulted in accept-
able expected and empirical precision for children and
adults. However, it is important to note that the model
reported for adults was estimated from pregnant and
post-partum women with Plasmodium vivax malaria.
Therefore, it is possible that adult patients with
Plasmodium falciparum malaria may display different
PK profiles than those simulated, and men may display
different profiles than non-pregnant women. Further-
more, Stepniewska et al. [21] only reported a BSV for
CL/F, but BSVs for the other PK parameters may well
exist in children. Thus the proposed sampling schedule
should be considered a truly “initial” optimal design,
and it is, therefore, recommended to vary sampling
within the windows to provide flexibility for the explor-
ation of alternative values for the PK and BSV parameters
in all patients with uncomplicated falciparum malaria.
Furthermore, taking additional samples, if possible, may
aid this exploration. As more studies of amodiaquine
and desethylamodiaquine are performed, the sampling
schedules proposed in this paper will be revised to pro-
vide designs that take into account newly reported values
of PK, BSV and residual error parameters.
Conclusions
Optimal design methodology allowed the determination of
robust blood sampling schedules that utilize current
knowledge of the pharmacokinetics of the partner drugs
and the practical issues involved with taking blood samples
from patients. The proposed designs are economical and
efficient, and should be considered when conducting popu-
lation PK studies of the partner drugs co-administered
with the artemisinin derivatives when intensive sampling
over the follow-up period is not possible. As with the
optimal designs derived for population PK studies of
dihydroartemisinin following oral artesunate [10], the
designs presented in this paper can be considered a
prototype for an iterative open access design support
tool to help investigators studying anti-malarial efficacy
and pharmacology in field studies. These will be pro-
vided by the clinical pharmacology arm of the World
Wide Antimalarial Resistance Network (WWARN) [28].
Additional file
Additional file 1: Displays the unpublished two-compartment model for
desethylamodiaquine and the results from the evaluation of the designs
[29].
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